Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
giovedì, ottobre 22
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Silence Therapeutics PLC
SLN
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$19.68
0.005
0.03%
Ult. Agg.: Oct 22, 11:28 AM
$19.67
N/A
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Fusioni e acquisizioni:
Silence Therapeutics (SLN) announced it will be acquired by Merck KGaA on Monday, October 19, 2026 for $1.1B paid in cash
Silence Therapeutics Financials
Silence Therapeutics (SLN) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Nasdaq Jumps Over 1% As Tech Stocks Gain: Investor Sentiment Improves, Greed Index Remains In ‘Extreme Fear’ Zone
Market sentiment improved slightly but stayed in extreme fear. Nasdaq rose 1.11%, while Silence Therapeutics surged 126% on Merck deal.
Avi Kapoor
Nasdaq Surges Over 1%; Fifth Third Bancorp Earnings Top Views
U.S. stocks mixed: Nasdaq +1.09%, S&P 500 +0.54%, Dow -0.12%. Tech led gains; utilities lagged. Oil fell, gold rose; Europe lower.
Avi Kapoor
PRO
Silence Therapeutics Q2 EPS $(0.09) Beats $(0.15) Estimate
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.15) by 40 percent. This is a 84.21 percent increase over losses of $(0.57) per share from
Benzinga Newsdesk
PRO
Silence Therapeutics Q1 EPS $(0.11) Beats $(0.21) Estimate, Sales $422.000K Miss $2.439M Estimate
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.21) by 47.62 percent. This is a 45 percent increase over losses of $(0.20) per share from
Benzinga Newsdesk
Silence Therapeutics Q4 Earnings Assessment
Benzinga Insights
PRO
Silence Therapeutics Q4 EPS $(0.27) Beats $(0.43) Estimate, Sales $34.000K Miss $6.730M Estimate
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.43) by 37.21 percent. This is a 200 percent decrease over earnings of $0.27 per share from
Benzinga Newsdesk
